FDA Advisory Committee recommends approval of Jardiance ® (empagliflozin) for cardiovascular indication in 12-11 vote
Endocrinologic and Metabolic Drugs Advisory Committee votes in favor of CV mortality benefit for JARDIANCE for adults with type 2 diabetes
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Jardiance | Research